IROBOT CORP(NASDAQ:IRBT) stock Fundamental Analysis

Fundamental Rating

Overall IRBT gets a fundamental rating of 1 out of 10. We evaluated IRBT against 67 industry peers in the Household Durables industry. IRBT may be in some trouble as it scores bad on both profitability and health. IRBT is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

IRBT had negative earnings in the past year.

IRBT had a negative operating cash flow in the past year.

The reported net income has been mixed in the past 5 years: IRBT reported negative net income in multiple years.

In multiple years IRBT reported negative operating cash flow during the last 5 years.

1.2 Ratios

With a Return On Assets value of -19.70%, IRBT is not doing good in the industry: 89.23% of the companies in the same industry are doing better.

The Return On Equity of IRBT (-87.91%) is worse than 89.23% of its industry peers.

		Industry Rank	Sector Rank
ROA	-19.7%
ROE	-87.91%
ROIC	N/A

ROA(3y)-24.41%

ROA(5y)-10.32%

ROE(3y)-70.34%

ROE(5y)-35.93%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

IRBT's Gross Margin of 22.52% is on the low side compared to the rest of the industry. IRBT is outperformed by 70.77% of its industry peers.

In the last couple of years the Gross Margin of IRBT has declined.

IRBT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	22.52%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-22.24%

GM growth 5Y-15.4%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

IRBT does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, IRBT has more shares outstanding

The number of shares outstanding for IRBT has been increased compared to 5 years ago.

The debt/assets ratio for IRBT is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of 1.03, we must say that IRBT is in the distress zone and has some risk of bankruptcy.

IRBT has a worse Altman-Z score (1.03) than 80.00% of its industry peers.

A Debt/Equity ratio of 1.24 is on the high side and indicates that IRBT has dependencies on debt financing.

IRBT has a worse Debt to Equity ratio (1.24) than 84.62% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.24
Debt/FCF	N/A
Altman-Z	1.03

ROIC/WACCN/A

WACC9.02%

2.3 Liquidity

IRBT has a Current Ratio of 1.45. This is a normal value and indicates that IRBT is financially healthy and should not expect problems in meeting its short term obligations.

IRBT has a worse Current ratio (1.45) than 78.46% of its industry peers.

IRBT has a Quick Ratio of 1.45. This is a bad value and indicates that IRBT is not financially healthy enough and could expect problems in meeting its short term obligations.

IRBT has a Quick ratio (0.94) which is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	1.45
Quick Ratio	0.94

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.94% over the past year.

IRBT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -13.14%.

The Revenue has been decreasing by -4.01% on average over the past years.

EPS 1Y (TTM)28.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%101.06%

Revenue 1Y (TTM)-13.14%

Revenue growth 3Y-14.61%

Revenue growth 5Y-4.01%

Sales Q2Q%3.9%

3.2 Future

The Earnings Per Share is expected to grow by 22.64% on average over the next years. This is a very strong growth

Based on estimates for the next years, IRBT will show a decrease in Revenue. The Revenue will decrease by -0.06% on average per year.

EPS Next Y39.17%

EPS Next 2Y35.59%

EPS Next 3Y22.64%

EPS Next 5YN/A

Revenue Next Year-17.33%

Revenue Next 2Y-9.11%

Revenue Next 3Y-0.06%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IRBT. In the last year negative earnings were reported.

Also next year IRBT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

IRBT's earnings are expected to grow with 22.64% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y35.59%

EPS Next 3Y22.64%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

IRBT does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

IROBOT CORP

NASDAQ:IRBT (2/4/2025, 8:00:02 PM)

After market: 7.9601 -0.14 (-1.73%)

8.1

+0.5 (+6.58%)

Chartmill FA Rating

GICS SectorConsumer Discretionary

GICS IndustryGroupConsumer Durables & Apparel

GICS IndustryHousehold Durables

Earnings (Last)02-05 2025-02-05/amc

Earnings (Next)N/A N/A

Inst Owners68.1%

Inst Owner Change-0.27%

Ins Owners3.67%

Ins Owner Change18.67%

Market Cap247.54M

Analysts47.5

Price Target11.7 (44.44%)

Short Float %12.48%

Short Ratio2.19

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)1

Avg EPS beat(2)71.85%

Min EPS beat(2)-8.35%

Max EPS beat(2)152.06%

EPS beat(4)3

Avg EPS beat(4)46.13%

Min EPS beat(4)-8.35%

Max EPS beat(4)152.06%

EPS beat(8)4

Avg EPS beat(8)-94.64%

EPS beat(12)6

Avg EPS beat(12)-70.37%

EPS beat(16)9

Avg EPS beat(16)-12.59%

Revenue beat(2)0

Avg Revenue beat(2)-8.32%

Min Revenue beat(2)-13.17%

Max Revenue beat(2)-3.48%

Revenue beat(4)1

Avg Revenue beat(4)-4.33%

Min Revenue beat(4)-13.17%

Max Revenue beat(4)1.44%

Revenue beat(8)2

Avg Revenue beat(8)-10.24%

Revenue beat(12)2

Avg Revenue beat(12)-11.98%

Revenue beat(16)6

Avg Revenue beat(16)-7.37%

PT rev (1m)0%

PT rev (3m)-11.57%

EPS NQ rev (1m)-2111.54%

EPS NQ rev (3m)-590.52%

EPS NY rev (1m)5.53%

EPS NY rev (3m)-28.32%

Revenue NQ rev (1m)-3.73%

Revenue NQ rev (3m)-40.97%

Revenue NY rev (1m)6.26%

Revenue NY rev (3m)-4.26%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.3
P/FCF	N/A
P/OCF	N/A
P/B	1.65
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-5.28

EYN/A

EPS(NY)-1.25

Fwd EYN/A

FCF(TTM)-1.03

FCFYN/A

OCF(TTM)-1.04

OCFYN/A

SpS26.75

BVpS4.91

TBVpS-0.96

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-19.7%
ROE	-87.91%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	22.52%
FCFM	N/A

ROA(3y)-24.41%

ROA(5y)-10.32%

ROE(3y)-70.34%

ROE(5y)-35.93%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-22.24%

GM growth 5Y-15.4%

F-Score3

Asset Turnover1.22

Health

		Industry Rank	Sector Rank
Debt/Equity	1.24
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	0.42%
Cap/Sales	0.01%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.45
Quick Ratio	0.94
Altman-Z	1.03

F-Score3

WACC9.02%

ROIC/WACCN/A

Cap/Depr(3y)41.4%

Cap/Depr(5y)61.98%

Cap/Sales(3y)1.09%

Cap/Sales(5y)1.68%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)28.94%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%101.06%

EPS Next Y39.17%

EPS Next 2Y35.59%

EPS Next 3Y22.64%

EPS Next 5YN/A

Revenue 1Y (TTM)-13.14%

Revenue growth 3Y-14.61%

Revenue growth 5Y-4.01%

Sales Q2Q%3.9%

Revenue Next Year-17.33%

Revenue Next 2Y-9.11%

Revenue Next 3Y-0.06%

Revenue Next 5YN/A

EBIT growth 1Y76.46%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year63.83%

EBIT Next 3Y24.01%

EBIT Next 5YN/A

FCF growth 1Y81.14%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y79.41%

OCF growth 3YN/A

OCF growth 5YN/A

IROBOT CORP (IRBT) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens